Skip to main content
. 2014 Jul 15;28:67.

Table 2 . Study variables in Mg treated and placebo group after 3 months intervention.

MgSO 4 group (n =25) Placebo group (n = 22)
End End p
Age (years) ________ ________ ________
Sex (male/female) ________ ________ ________
Duration of diabetes (years) ________ ________ ________
BMI (kg/m2) 26.41 ± 3.29 27.28 ± 5.13 Not significant
Systolic blood pressure ( mm Hg) 102.8 ± 9.51 117.2 ± 3.48 <0.001
Diastolic blood pressure ( mm Hg) 62.85 ± 7.55 70 ± 7.07 <0.05
Serum Mg (mg/dl) 2.16 ± 0.36 2.23 ± 0.50 Not significant
Urine Mg (mg/dl) 5.99 ± 2 4.56 ± 1.72 <0.05
Calcium to magnesium ratio 4.64 ± 1.46 5.21 ± 1.65 Not significant
Fasting blood glucose (mg/dl) 125.8 ± 6.52 136.5 ± 7.94 <0.0001
2hr PP blood glucose (mg/dl) 189.1 ± 60.05 247.8 ± 86.74 <0.01
HbA1C (%) 7.90 ± 1.68 7.61 ± 1.59 Not significant
HOMA-IR index 5.01 ± 2.47 4.65 ± 3.48 Not significant
Fasting plasma insulin (qIU/ml) 15.90 ± 8.02 13.35 ± 11.53 Not significant
Triglycerides (mg/dl) 158.7 ± 77.16 175.5 ± 107.5 Not significant
Total cholesterol (mg/dl) 176.2 ± 48.33 182.7 ± 56.23 Not significant
LDL cholesterol (mg/dl) 93.63 ± 24.58 120.4 ± 34.86 <0.01
HDL cholesterol (mg/dl) 41.7 ± 8.79 43.65 ± 11.20 Not significant
Non HDL cholesterol (mg/dl) 125.30 ± 23.19 152.16 ± 37.05 <0.001
Hemoglobin concentration (gr/dl) 13.46 ± 1.51 13.18 ± 1.71 Not significant
Aspartate transfrase (IU/ml) 18.15 ± 10.40 24.92 ± 12.12 Not significant
Alanin transfrase (IU/ml) 22.30 ± 2.83 33.93 ± 5.70 <0.05
Metformin dosage ( mg ) 1371.42 ± 625.21 1750 ± 379.77 <0.01
Glibenclamid dosage ( mg ) 10.76 ± 7.10 13.31 ± 6.18 Not significant
Enalapril dosage (mg) 13 ± 4.6 23 ± 6.6 <0.01
Atorvastatin dosage (mg) 15 ± 1.88 17.5 ± 3.65 Not significant

Data are means ± SD.